- Home
- CCM vs NRSN Comparison
CCM vs NRSN Comparison
Compare CCM & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCM | NRSN |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 17.7M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCM | NRSN |
|---|---|---|
| Price | $4.77 | $0.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 46.0K | ★ 216.9K |
| Earning Date | 05-12-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $0.39 |
| 52 Week High | $6.98 | $1.33 |
Technical Indicators
Market Signals| Indicator | CCM | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 31.40 |
| Support Level | $4.41 | $0.39 |
| Resistance Level | $5.52 | $0.74 |
| Average True Range (ATR) | 0.60 | 0.07 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 39.63 | 30.79 |
Price Performance
Historical ComparisonAbout CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.